NCT05285917View on ClinicalTrials.gov

Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2027

Conditions
Sickle Cell Anemia in ChildrenSickle Cell Disease
Interventions
DRUG

Hydroxyurea

Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.

Trial Locations (1)

Unknown

RECRUITING

Hospital Geral dos Cajueiros, Luanda

Sponsors

Lead Sponsor

Brown University

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Novartis

INDUSTRY

lead

Brown University

OTHER

NCT05285917 - Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa | Biotech Hunter | Biotech Hunter